+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death



Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death



Basic Research in Cardiology 81(1): 40-53



The antifibrillatory, antithrombotic and hemodynamic properties of intraventricular prostacyclin (PGI2) application were studied in a conscious canine model of sudden cardiac death. In anesthetized dogs, a wire electrode was implanted into the left circumflex coronary artery (LCX) and acute myocardial ischemia was produced by 90 min occlusion of the left anterior descending coronary artery (LAD) followed by reperfusion. An intracardiac pressure transducer measured ventricular pressure, heart rate, filling pressure and dP/dt. The ECG was obtained from subcutaneous chest needles. Six days later while in ambulatory state, a 180 .mu.A DC current was applied for 4 h to the LCX intimal lining in Tris-HCl (n=10) and PGI2-treated dogs (50 and 100 ng/kg per min, 11 and 12 dogs, respectively). Myocardial injury and coronary thrombosis induced by electrical stimulation produced ventricular fibrillation in all vehicle-treated dogs at 145 .+-. 33 min (mean .+-. S.D.). In PGI2-treated hearts only 2 animals fibrillated at 150 .+-. 29 min and 180 .+-. 52 min following 50 and 100 ng/kg per min of the prostanoid, respectively. Thus, 18/23 PGI2-treated dogs survived 4 h electrical stimulation of the artery. Within the LAD perfusion zone infarction was observed of equal volumes in vehicle and PGI2-treated animals. No ischemic occurred distal to the LCX coronary thrombosis. Ventricular pressure fell in all groups. Heart rate increased in the controls and those animals treated with 50 ng/kg per min PGI2 while 100 ng/kg per min PGI2 increased heart rate by 22 .+-. 5% (P < 0.05). Filling pressure increased in controls but fell in the PGI2-treated hearts. The results indicate that PGI2 can prevent ventricular fibrillation resulting from acute ischemia at a site distant to previous myocardial ischemia with superimposed intimal injury and coronary thrombosis. The PGI2 properties are due to prevention of coronary thrombosis and the occlusion of the artery. Antifibrillatory effects of the prostanoids are suggested.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 006206637

Download citation: RISBibTeXText

PMID: 3521579

DOI: 10.1007/bf01907426


Related references

Prostacyclin on ventricular fibrillation in a conscious canine model of sudden coronary death. Naunyn-Schmiedeberg's Archives of Pharmacology 321(Suppl.): R54, 1982

Win 54177 4 prevents ventricular fibrillation in a canine model of sudden death. FASEB Journal 2(5): ABSTRACT 7325, 1988

Epoprostenol prevents postischemic ventricular fibrillation and improves outcome in a canine model of sudden death. Journal de Pharmacologie 16(2): 139-158, 1985

Epoprostenol (PGI2) prevents postischemic ventricular fibrillation and improves outcome in a canine model of sudden death. Journal de Pharmacologie 16(2): 139-157, 1985

MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. Journal of Cardiovascular Pharmacology 25(2): 314-323, 1995

Tedisamil protects against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 10(3): A33, 1996

Tedisamil Attenuates Ventricular Fibrillation in a Conscious Canine Model of Sudden Cardiac Death. Journal of Cardiovascular Pharmacology and Therapeutics 1(4): 313-324, 1996

5-hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death. European Journal Of Pharmacology. 306(1-3): 99-106, 1996

Study on mechanisms of occurrence of ventricular fibrillation in a new canine model of sudden cardiac death induced by 3 4 diaminopyridine. Japanese Circulation Journal 55(Suppl. A): 417, 1991

Ventricular fibrillation in a conscious canine model of sudden cardiac death Effects of MS-551, a multiple dose regimen. FASEB Journal 8(4-5): A78, 1994

The KATP channel antagonist 5-hydroxydecanoate fails to protect against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 9(3): A605, 1995

Implantable cardioverter defibrillator for prevention of sudden cardiac death in patients with ventricular tachycardia and ventricular fibrillation: ICD therapy in sudden cardiac death. Pacing and Clinical Electrophysiology 16(3 Pt 2): 511-518, 1993

Effect of flecainide acetate on ventricular tachycardia induction and ventricular fibrillation prevention in a conscious canine model of sudden death. Journal of the American College of Cardiology 7(2 Suppl. A): 84A, 1986

Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. American Heart Association Monograph (82): IV-125, 1981

Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death. Pharmacology 37(3): 171-186, 1988